文献速递乳腺癌放疗

乳腺癌超低分割放疗的临床结局与单中心经验

Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer.
PubMed 文献 · Adv Radiat Oncol · 2025-11-12

本研究基于COVID-19疫情及FAST-Forward研究发表背景,快速在早期乳腺癌患者中实施超低分割放疗(U-HFRT,26 Gy/5次),并与中等低分割放疗(M-HFRT,40.05 Gy/15次)比较皮肤毒性。共评估320例0-II期乳腺癌患者,U-HFRT组133例(41.6%),M-HFRT组187例(58.4%)。多因素分析显示M-HFRT组放疗期间1级以上皮肤毒性显著更多(OR=32.3,P<.001),而放疗后1-90天M-HFRT组1级以上毒性更少(OR=0.36,P=.014)。

要点

  • U-HFRT(26 Gy/5次)用于0-II期乳腺癌术后全乳放疗,放疗期间急性皮肤毒性低于M-HFRT。
  • 放疗后1-90天M-HFRT组1级以上皮肤毒性反而更少(OR=0.36,P=.014)。
  • 放疗后90天以上皮肤毒性总体发生率低,但需更长期随访确认局部控制与晚期正常组织毒性。

核心结论

  • U-HFRT(26 Gy/5次)在0-II期乳腺癌术后全乳放疗中急性皮肤毒性低于M-HFRT(40.05 Gy/15次),可作为特定患者的标准方案。

研究设计与样本

  • 单中心回顾性研究,连续纳入2020年5月至2021年3月接受辅助全乳放疗的0-II期乳腺癌患者320例,分为U-HFRT组133例(41.6%)和M-HFRT组187例(58.4%)。

主要发现

  • U-HFRT组诊断中位年龄65.4岁(范围57-73),71%为激素受体阳性浸润性疾病,18%为导管原位癌,33%接受瘤床加量。
  • U-HFRT更多用于年龄较大、激素受体阳性且未接受瘤床加量的患者(P<.001)。
  • 多因素分析显示M-HFRT组放疗期间1级以上皮肤毒性显著更多(OR=32.3,P<.001)。
  • 调整瘤床加量、年龄和化疗后,放疗后1-90天M-HFRT组1级以上皮肤毒性更少(OR=0.36,P=.014)。
  • 放疗后90天以上皮肤毒性总体发生率低。

关键数值与推荐

  • U-HFRT方案为26 Gy/5次,M-HFRT方案为40.05 Gy/15次,均给予全乳放疗。
  • 皮肤毒性采用RTOG放射损伤分级评估,时间点为基线/放疗期间、放疗后1-90天及放疗后90天以上。

临床怎么用

  • 对年龄较大、激素受体阳性且无需瘤床加量的0-II期乳腺癌患者,可考虑选择U-HFRT(26 Gy/5次)以降低放疗期间急性皮肤毒性。
  • 需注意放疗后1-90天M-HFRT组皮肤毒性反而更少,临床随访中应关注不同分割方案毒性时间分布的差异。
  • 长期局部控制和晚期正常组织毒性需更长时间随访确认。

局限性

  • 单中心回顾性研究,非随机分组,存在选择偏倚。
  • 随访时间较短,无法评估长期局部控制和晚期正常组织毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prompted by COVID-19 and publication of the FAST-Forward study, our institution rapidly implemented ultrahypofractionated radiation therapy (U-HFRT) for patients with early-stage breast cancer. Our objective was to evaluate our early experience and toxicity outcomes for U-HFRT. METHODS AND MATERIALS: Patients with consecutive stage 0-II breast cancer treated with adjuvant whole breast radiation therapy (RT) were evaluated. Patient demographics and treatment characteristics were extracted and categorized into 2 cohorts: U-HFRT, 26 Gy/5 fractions (F) and M (moderate)-HFRT, 40.05 Gy/15F. Physician-assessed skin toxicity was evaluated using the Radiation Therapy Oncology Group radiation morbidity scale at baseline/during RT, 1 to 90 days post-RT and >90 days post-RT. Descriptive statistics summarized patient demographics and treatment characteristics and were stratified based on dose fractionation. A multivariable logistic model evaluated associations between toxicity and fractionation. RESULTS: Between May 2020 and March 2021, 320 patients were evaluated: 133 (41.6%) received U-HFRT and 187 (58.4%) received M-HFRT. For the U-HFRT cohort, median age at diagnosis was 65.4 years (range, 57-73), 71% had hormone receptor-positive invasive disease, and 18% had ductal carcinoma in-situ. All patients received whole breast RT, and 33% received a boost. U-HFRT was used more in patients who were older, hormone receptor-positive, and did not receive a boost (P < .001). On multivariable analysis, M-HFRT patients experienced significantly more grade 1+skin toxicity during RT (odds ratio = 32.3, P < .001), while 1 to 90 days post-RT, M-HFRT patients experienced less grade 1+ toxicity (odds ratio = 0.36, P < .014) after adjusting for boost, age, and chemotherapy. Rates of skin toxicity >90 days post-RT were low overall. CONCLUSIONS: This study reports real-world clinical outcomes of patients with stage 0-II breast cancer treated with U-HFRT. We observed low rates of acute skin toxicity compared to M-HFRT, confirming its acceptability as a standard regimen for select patients. Longer term follow-up would be necessary to confirm clinical outcomes in terms of both local control and late normal tissue toxicity.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Othman H, Barry A, Fyles A, et al. Clinical Outcomes and Institutional Experience of Ultrahypofractionated Radiation Therapy in Patients With Breast Cancer. Adv Radiat Oncol. 2025. PMID: 41541755. doi:10.1016/j.adro.2025.101948

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。